This website uses cookies to improve the site and user experience. By continuing to browse this site,
you agree to accept our use of cookies. For more information, please review our Cookies Policy
ESMO 2021
Presentations
Enfortumab Vedotin | Urothelial Carcinoma | Abstract #3557
Systematic Literature Review (SLR) and Network Meta-Analysis (NMA) of First-Line (1L) Therapies for Locally Advanced/Metastatic Urothelial Carcinoma (la/mUC)
Enfortumab Vedotin | Urothelial Carcinoma | Abstract #3252
Treatment Patterns Among Patients With Advanced Urothelial Carcinoma (aUC) in the US
Enfortumab Vedotin | Urothelial Carcinoma | Abstract #1151
Analysis of Hard-to-Treat Subgroups From EV-301, a Phase 3 Trial of Enfortumab Vedotin vs Chemotherapy for Previously Treated Advanced Urothelial Carcinoma